2. Academic Validation
  3. In Vivo Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model

In Vivo Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model

  • Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00909-19. doi: 10.1128/AAC.00909-19.
Sachin S Bhagwat 1,  Hariharan Periasamy 2,  Swapna S Takalkar 2,  Rajesh Chavan 2,  Pavan Tayde 2,  Amol Kulkarni 2,  Jaikumar Satav 2,  Vineet Zope 2,  Mahesh Patel 2
Affiliations

Affiliations

  • 1 Wockhardt Research Centre, Aurangabad, India sbhagwat@wockhardt.com.
  • 2 Wockhardt Research Centre, Aurangabad, India.
PMID: 31208999 DOI: 10.1128/AAC.00909-19
Abstract

Levonadifloxacin is a novel benzoquinolizine subclass of fluoroquinolone, active against quinolone-resistant Staphylococcus aureus A phase 3 trial for levonadifloxacin and its oral prodrug was recently completed. The present study identified area under the concentration-time curve for the free, unbound fraction of a drug divided by the MIC (fAUC/MIC) as an efficacy determinant for levonadifloxacin in a neutropenic murine lung Infection model. Mean plasma fAUC/MIC requirement for static and 1 log10 kill effects against 9 S. aureus were 8.1 ± 6.0 and 25.8 ± 12.3, respectively. These targets were employed in the selection of phase 3 doses.

Keywords

ABSSSIs; MRSA; levonadifloxacin.

Figures
Products